Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation
Excerpt from the Press Release:
BOSTON, March 30, 2022 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data at the Mitochondrial Biochemistry in Health and Disease Symposium in Breckenridge, CO and dosing of the first subject in its Phase 1 clinical trial of SBT-272.
The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington’s disease. In the study, mice were treated for up to 8 weeks with daily SBT-272 and displayed significantly improved motor function compared to vehicle-treated mice. SBT-272-treated mice also showed improved metabolism in multiple brain regions of the diseased animals, assessed in vivo using PET imaging.
The Phase 1 clinical trial is a double-blind, placebo controlled safety study enrolling up to 64 healthy subjects across multiple cohorts. SBT-272 is being administered via subcutaneous injection. As a primary objective, the study will evaluate safety and tolerability of single and multiple ascending doses of SBT-272. Secondary objectives include an analysis of the pharmacokinetic profile of SBT-272 and identification of the appropriate dose range for Phase 2 testing.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?